Since 2010, NovelBio has been a key player in the NGS industry, supporting over 1,000 clients in completing more than 10,000 major projects.

NovelBio operates at the forefront of life sciences, partnering with leading global scientists to decode the fundamental principles of biological complexity.

We maintain sustained investment in core innovations including next-generation sequencing (NGS), single-cell multi-omics, spatial technologies, and bioinformatic algorithms.

This commitment to R&D fuels our continuous leadership, providing an enduring source of innovation and competitive advantage for our "Intelligent Creation" and translational pipelines.

Empowering R&D with a full portfolio of proprietary patents, delivering domestic single-cell multi-omics solutions through our integrated product ecosystem.

NovelBio Creation translates cutting-edge research into stable, efficient, and intelligent domestically developed high-end life science instruments and reagents. This ensures core tool autonomy, securing strategic control over pricing.

As a benchmark in import substitution, NovelBio Creation delivers solutions rivaling global top-tier products in performance – offering high quality, efficiency, and cost-effectiveness. These meet the growing demand for high-throughput, high-precision, and automated equipment in both research and clinical settings.

Our robust manufacturing capability provides a solid foundation for translating scientific innovation into practical applications while meeting global market needs. It also serves as a strategic safeguard against potential bottlenecks in key technologies.

We are building a world-leading bioinformatics big data system that integrates knowledge bases, databases, high-performance computing, and artificial intelligence into a unified platform.

The NovelBio Bioinformatics Big Data System delivers a secure, efficient, user-friendly, and intelligent all-in-one solution for the analysis, storage, management, and collaboration of multi-omics big data.

More than just a tool, it serves as a central hub for data value transformation—interpreting the complexities of life rapidly, accurately, and comprehensively. It turns cold raw data into interpretable biological insights, providing robust support for medical translation.

As multi-omics data grows exponentially and AI integration deepens, the NovelBio system will continue to evolve, becoming essential infrastructure and the intelligent engine for life science research and precision medicine.

We efficiently and precisely translate cutting-edge research and NovelBio's platform technologies into actionable solutions for clinical diagnosis, drug development, and health management. This process represents the ultimate realization of our strategic value, driving sustainable growth for the company while creating substantial social impact and benefiting countless lives.

These four integrated divisions form a self-reinforcing innovation cycle, demonstrating not only NovelBio's ambition to decode life's complexities but also representing China's transition from a follower to a global leader in life sciences.

We firmly believe that through sustained commitment to these strategic pillars, NovelBio will not only steer the trajectory of life science technology but also realize its vision as the "pioneer in the Single-Cell Medicine 2.0 era." By shaping global precision medicine with China's solutions, we are opening a new chapter in human health management. With unwavering resolve, NovelBio is defining the future of life sciences.